April 13, 2021

Progentec Launches aiSLE MGMT | A Care Management Platform for Lupus (SLE) Patients and Clinicians

aiSLE MGMT lupus Flare Risk Index Image
Credit: PRNewsfoto/Progentec Diagnostics, Inc.

Progentec, a diagnostic and digital technology organization focused on the proactive management of autoimmune diseases, has announced the release of aiSLE MGMT, a comprehensive disease management platform that combines biomarkers and digital care delivery. aiSLE MGMT transforms immunological and digital data into clinical reports and provides patients with access to a health coach and lupus care tools through a mobile application. aiSLE MGMT consists of two Progentec-developed technologies, aiSLE DX and AutoimmuneCorner.

What is aiSLE MGMT?

aiSLE MGMT combines two Progentec-developed technologies to provide rheumatologists and other clinicians with unparalleled insight into lupus disease activity and the patient experience.

  • aiSLE DX is a collection of lupus-specific algorithms developed in conjunction with protein-based blood tests that analyze indicative biomarkers’ presence. The first of these tests, the aiSLE DX Flare Risk Index (currently available), identifies the risk of a lupus patient experiencing a disease flare in the next twelve weeks.
  • [AutoimmuneCorner] is a patient-first digital health platform and mobile app that provides patients with: health coaching (via real-time video sessions and asynchronous messaging), a wearable device to track activity, sleep, and heart rate (aiSLE™ MGMT enrollees receive a Withings Steel HR smartwatch), lupus tracking tools including validated patient-reported outcome measures (PROs), and health literacy courses.

According to Progentec, the data generated by these technologies is synthesized using artificial intelligence (A.I.) and provided to clinicians managing lupus patients in clinical reports used to inform care decisions.

New types of data are the key to successful lupus management. With the right data, clinicians can take proactive steps to identify effective treatments and respond to lupus disease activity changes quickly. aiSLE MGMT offers clinicians the insights needed for both.

Arif Sorathia, Chief Technology Officer at Progentec

A Look Inside aiSLE MGMT: What is aiSLE DX?

Progentec’s aiSLE DX Flare Risk Index is an advanced blood test that can help inform the risk of a systemic lupus erythematosus-related flare within the next 12 weeks. aiSLE DX tests were developed from studies of SLE patients presenting for treatment at several lupus Centers of Excellence in the United States. The studies were conducted in both European and African Americans SLE patients. They indicated the assay’s ability to potentially provide a robust, predictive gauge of impending disease flare with high degrees of accuracy. Patients in each study with confirmed disease flares were matched after a baseline pre-flare assessment, with SLE patients without impending flare (non-flare) and healthy controls.

To learn more about the development of Progentec’s aiSLE DX, refer to the Progentec published research webpage.

What is Autoimmune Corner?

Progentec’s AutoimmuneCorner is a smartphone app for patients that makes it possible to track and manage complex health conditions then share relevant information with their clinician. The app provides:

  • Interactive sessions with a health coach
  • Custom and validated patient-reported outcomes (PRO) assessments
  • Wearable device integration for sensor data
  • Disease-specific health interventions

aiSLE MGMT Highlighted Feature: AutoimmuneCorner in Action

One highlighted feature within the Progentec aiSLE MGMT platform, is the ability to unlock proactive treatment decisions with the AutoimmuneCorner Report. The AutoimmuneCorner Report provides insights to doctors in-between visits that can drive treatment plan changes. The report provides a breakdown of objective and subjective patient measures, standardized to the individual patient. As a result, the provider can quickly identify changes in activity, sleep, and symptoms. 

Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus (SLE) is the most common type of lupus. SLE is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. As a result, it can affect the joints, skin, brain, lungs, kidneys, and blood vessels. There is no cure for lupus, but medical interventions and lifestyle changes can help control it. SLE can affect people of all ages, including children. However, SLE is two to three times more common among women of color—African Americans, Hispanics/Latinos, Asians, Native Americans, Alaska Natives, Native Hawaiians, and other Pacific Islanders—than among Caucasian women.

SLE is an extremely challenging disease to manage clinically. Challenges in achieving positive lupus health outcomes stem from the complex underlying biology of the autoimmune disease and the impact of Social Determinants Of Health (SDOH), notably access to care and health literacy. As a result, research has found that individual behavior, often driven by social determinants, accounts for up to 40 percent of premature death risk. 

The Power of Digital Health Tools

COVID-19 has forced us to question what’s possible in healthcare delivery and to challenge our thinking. And with that, many health systems and providers have learned that digital health tools are crucial for improving outcomes and enhancing the patient experience. With that, we’ve seen both patients and providers express positive responses to these innovations. As the adoption of digital health tools continues to grow, these technologies will continue to hold the greatest promise for improved outcomes.

Confidence in digital health technologies’ and tools’ potential continues to progress as health systems continue to invest in a more digital health care experience – focusing on connecting with, communicating with, and monitoring patients outside the health system’s walls. While it’s reassuring to see health systems embrace the growing demand by consumers for a more digital care experience, successful patient/health system adoption is much more than investing money in and implementing new technology. In the end, we should take the best of what we learned during a hard time to continue to provide the best care possible at all times.

About Progentec Diagnostic

Progentec is committed to improving access and health outcomes for patients with autoimmune diseases by combining clinically validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners worldwide, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.

Logan Harper

With an M.S. in Organizational Leadership, my background lies within the healthcare operations and sales sector, specifically within the digital health/ digital therapeutics arena. I have a proven track record of developing and implementing effective sales strategies, establishing organizational partnerships, and creating effective product/service/sales training programs and collateral.

View all posts by Logan Harper →

Leave a Reply

%d bloggers like this: